Sentences with phrase «program at an affordable rate»

The partnership between the Student Loan Finance Corporation and the Independent Community Bankers of America is aimed at providing competitive student loan programs at affordable rates with personable customer service.

Increased revenue by implementing a shared sail program at an affordable rate for local students to be able to get back on the water and practice their skills.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

With USDA mortgage rates in the 3s, and home prices still within affordable ranges, it's time for buyers to look closely at the USDA home loan program.

The program also played into what de Blasio considers his biggest success yet in forcing developers to include affordable housing; the 1,723 - unit Astoria Cove project along the Queens waterfront, where 27 percent of the units are to be available at below market - rate rents.

Ms. Olatoye's proposed program would use open space at the developments to construct 13,500 below - market - rate apartments — contributing to the mayor's ambitious affordable housing agenda — and 3,500 units for more upscale tenants.

Researchers at UCLA have that found states that expanded Medicaid coverage under the Affordable Care Act saw a significant increase in rates of health insurance among low - income adults compared with states that did not expand the program.

HARP: The Home Affordable Refinance Program is a federal government program that helps homeowners refinance their mortgage at a loweProgram is a federal government program that helps homeowners refinance their mortgage at a loweprogram that helps homeowners refinance their mortgage at a lower rate.

Loan Protection Coverage Mainstreet offers several protection programs to meet members» personal insurance needs at the most affordable rates.

Under the Direct Loan program, individuals or families receive direct financial assistance directly from the Rural Housing Service in the form of a home loan at an affordable interest rate.

Under the new Home Affordable Refinance Program created by the federal government, eligible homeowner can now refinance their homes at affordaAffordable Refinance Program created by the federal government, eligible homeowner can now refinance their homes at affordableaffordable rates.

To assist homeowners with negative equity in refinancing at lower interest rates, over longer loan terms or with less risky loan structures, the government rolled out the Home Affordable Refinancing Program.

With USDA mortgage rates in the 3s, and home prices still within affordable ranges, it's time for buyers to look closely at the USDA home loan program.

NACA - A home purchase program that provides housing counseling and access to a mortgage at an affordable rate.

The Home Affordable Refinance Program (HARP) was created to help underwater homeowners whose loans were guaranteed be Fannie Mae or Freddie Mac to be able to refinance at today's current low interest rates.

Traditional fixed - and adjustable - rate mortgages are available, along with loans through government - backed Fannie Mae and Freddie Mac, as well as the Home Affordable Refinance Program (HARP) that help underwater or near - underwater homeowners refinance their home at a lower rate.

Info for Second Mortgages Comparing Second Mortgage Premium Second Mortgages 2nd Mortgage 125 % Second Mortgage Second Mortgage Refinance Stated Income Second Mortgage Second Mortgage Brokers Second Mortgage Loans Second Mortgage Rates 80 % Second Mortgages 90 % Second Mortgage Loans 95 % Second Mortgage 100 % Second Mortgage 115 % Fixed Rate Second Mortgage 125 % Fixed Rate Second Mortgage 40 - Year Second Mortgage 2nd Loan Mortgages Second Mortgage Pay off Tax Lien Second Mortgage - Negative Amortization Second - Mortgage Pre-Payment Penalty Fixed Rate Second Mortgage Second Mortgage Home Loan 2nd Mortgage with Neg Am Non Conforming Second Mortgage Loans Second Mortgage Credit Cash Out Second Mortgage Second Mortgage Interest Rates Second Mortgage Loan Rates Modular Home Second Mortgage Second Mortgage Information Second Mortgage Company Second Mortgage California Modular Home Second Mortgages Affordable Second Mortgage Low Closing Cost Second Mortgage Preferred Second Mortgage Loans Low Rate Second Mortgage Popular Second Mortgages Home Mortgage Refinancing Second Seller Second Mortgage Loans Bill Consolidation 2nd Mortgages Second Mortgage Specials Fast & Easy Second Mortgages Second Mortgage Qualification Second Mortgage Products Simple Interest Second Mortgages No Income Verified Second Mortgages Second Mortgage Programs State Guide Second Mortgages No Cash at Closing Second Mortgages Financing a New Business with a 2nd Mortgage High LTV Second Mortgage Loans 2nd Home Construction 125 Concurrent 1st & 2nd Mortgage Refinance Second Mortgage Rate Update for Cash Out Refinancing Second Mortgage Credit Lines Used for Avoiding Foreclosure How to Get Approved for a Second Mortgage Combine First and Second Mortgage Loans Second Mortgage Market Update Second Mortgage Loans for Hard Times Second Mortgage Loans to Refinance Credit Card Debt Second Mortgage Loan Update for 125 % Low Interest Loans Cash Out Loans for Homeowners

Our new membership program provides an exciting outdoor alternative for exercise at a much more affordable rate than a gym membership.

Americas Best Value Inn's 43 rooms offer guests comfort, quality and service at an affordable rate, along with free continental breakfast, high - speed Wi - Fi and HBO premium programming.

HousEART is a program of the Smith Hill Community Development Corporation that invites artists to make art on vacant neighborhood houses owned by the SHCDC that will soon be renovated and offered for rent at affordable rates.

North Star has a special subsidized program to replace your health coverage at an affordable rate.

California's Low Cost Automobile (CLCA) Insurance program was established by the Legislature in 1999 and exists (pursuant to California Insurance Code Section 11629.7) as a program designed to provide income - eligible, good drivers with liability insurance protection at affordable rates as a way to meet California's mandatory auto insurance law.

We also review your policy rates with our exclusive RateGuard ™ program at every renewal, checking for any rate increases and shopping for more affordable coverage if needed.

Amazon's Prime Exclusive program is a great way to score solid, affordable Android smartphones at a discounted rate, all for putting up with some lockscreen ads.

For example, one proposal would fix the rate at which some affordable housing properties in the LIHTC program generate tax credits, making the program more predictable for developers and investors.

Although 75 percent of the houses that were rehabbed through the affordable loan program have not yet been resold at market rates, there are worries that the area has been restored too quickly.

Under the Direct Loan program, individuals or families receive direct financial assistance directly from the Rural Housing Service in the form of a home loan at an affordable interest rate.

HARP: The Home Affordable Refinance Program is a federal government program that helps homeowners refinance their mortgage at a loweProgram is a federal government program that helps homeowners refinance their mortgage at a loweprogram that helps homeowners refinance their mortgage at a lower rate.

Thanks to new changes to the Home Affordable Refinance Program (HARP) guidelines, more homeowners can refinance at today's lower rates — even if their homes have declined in value.